Dr. Pardo, Infectious Diseases Physician and Ambulatory Care Provider at the James A Haley Veterans Hospital, discusses how to manage routine adult vaccinations during the 2020 COVID-19 pandemic. She first discusses the transmission of Coronavirus in vaccination settings and how to determine whether it is safe for patients to come in for vaccinations. She next discusses when the deferring of vaccination visits is appropriate, such as in those persons with suspected or confirmed COVID-19 disease. As we approach the winter season, Dr. Pardo shares information about the importance of influenza vaccination in all adult patients. Lastly, Dr. Pardo discusses catch up strategies for vaccination in pandemic delayed patients as well as reference sources for the clinician to access up to date vaccination recommendations.
Dr. Fredenrich discusses the origins and consequences of the vaccine hesitancy movement in this informative podcast. She begins by tracing back recent anti-vaccine sentiment to the now retracted 1998 Lancet article published by Dr. Andrew Wakefield and its initial origins to 19th Century London. She relates the decades-long success story of vaccines in reducing childhood and adult morbidity from vaccine preventable diseases such as measles, chicken pox, and polio. She identifies some of the factors that cause vaccine hesitancy among new parents. She then highlights some of the relevant laws relating to vaccine exemptions across the U.S. Next, Dr. Fredenrich mentions some of the falsely maligned components of vaccines that are commonly cited as a reason for parent reluctance. She also associates the significance of social media in producing vaccine sentiment among parents and adults. Lastly, she relates how medical providers can use their trusted influence with their patients and their families to help them make the right decisions about vaccines.
Dr. Hernandez reviews one of the more under-recognized manifestations of COVID-19 infection: conjunctivitis. Originally recorded in May 2020, the talk reviews basic epidemiology about Coronavirus infection and then focuses upon the ocular manifestations. She notes that ACE-2 receptors are extensively noted in eye tissue, including the human retina, retinal pigment, and conjunctiva. She next describes the epidemiology of Coronavirus conjunctivitis. Dr. Hernandez then discusses the potential for transmission of COVID-19 through tears. After reviewing the outcomes and prognosis of Coronavirus eye disease, she closes by discussing a couple of helpful case studies.
Drs. John T Sinnott, Kami Kim, and Seetha Lakshmi, distinguished Infectious Diseases faculty at the University of South Florida, discuss updates to the 2019 Coronavirus pandemic. Dr. Sinnott begins by tracing the beginnings of the pandemic, from its sylvatic origins in bats likely through an intermediary vector (a pangolin) to its first human hosts. Dr. Sinnott follows the pandemic to America, and shares some of the early assessments about the threat of the disease which were unheeded. Next, Dr. Sinnott discusses our current understanding of the pathophysiology of the SARS-2 Coronavirus, including its route of infection in the human host. Dr. Kim next discusses the specifics of Coronavirus testing, including the proper use and interpretation of molecular and antibody-based tests. Dr. Lakshmi then discusses current Coronavirus-targeted therapies, including convalescent plasma, remdesivir, dexamethasone, and monoclonal antibody-based treatments. Dr. Sinnott closes by discussing post-COVID syndromes and how the pandemic will likely end.
Dr. Katzman reviews the importance of toxins in the manifestation of bacterial diseases. Bacterial toxins cause injury by producing tissue damage to the host during a bacterial infection. The different mechanisms by which bacterial toxins can produce injury are reviewed, including via intracellular and cell surface targets, membrane damage, superantigens, and involvement of the extracellular matrix. Dr. Katzman next reviews several well-known bacterial toxins, including Staphylococcal and Streptococcal toxins and Pseudomonas exotoxin A. Lastly, toxin therapies, such as toxoids and passive immunization are reviewed.
Dr. Anthony Cannella, Associate Director of Epidemiology at the James A Haley Veterans Hospital, presents a series of clinical cases from his years in infectious diseases practice. The cases are presented in a visual, interactive format. From a virtual session originally recorded on August 19, 2020.
Dr. Mercurio reviews antimicrobial susceptibility testing methods and explains how this data reported with culture results can be best used to make informed antibiotic treatment decisions. Dr. Mercurio begins by discussing the difference between MIC and MBC, and the misconceptions about MIC values for different antibiotic agents. Next, she reviews recent changes in the susceptibility breakpoints for several bacterial organisms, including Enterococcus spp., Staphylococcus aureus, Enterobacteriaceae, and Pseudomonas. Lastly, she reviews the resistance issues with the “SPACE/SPICE” bacteria as well as inducible clindamycin resistance, and closes with comments on heteroresistance issues in bacterial populations.
Dr. John Greene, Chief of Infectious Diseases at Moffitt Cancer Center, reviews disorders involving the gastrointestinal tract. Syndromes discussed include Cholera, traveller’s diarrhea, Typhoid fever, Salmonellosis, Campylobacter, pathogenic E coli, Echinococcosis, aeromonas, and Vibrio. Dr. Greene presents the topics in a fast paced, photo quiz format.
In a follow-up to his presentation recorded in May 2020, Dr. Oehler presents ten current coronavirus myths or assertions circulating online today and comments on their legitimacy or inaccuracy. Topics covered include the importance of wearing masks, the differences in types of masks for the public, whether recent protests led to increased cases of COVID-19 in those communities, the phenomenon of “COVID parties,” the adequacy of U.S. coronavirus testing, the long term effects of COVID-19, and whether a Coronavirus vaccine will be available by early 2021.